Gilead Sciences, Inc. (NASDAQ: GILD) announced that The New England Journal of Medicine published results from the Phase 3 ASCENT-04/KEYNOTE-D19 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE